Clinical trials: Acute Lymphoblastic Leukaemia, open to volunteers
Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally administered AZD3632 in participants with advanced haematologic…
- Conditions
- Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic Syndromes
- Trial name
- MOMENTUM (NCT07155226)
- Testing
- AZD3632, Posaconazole
- Where
- 30 sites in United States, Australia and 7 more
- Volunteers
- 85 people
- Sponsor
- AstraZeneca
B-Cell Acute Lymphoblastic Leukaemia
Blinatumomab Consolidation in Real World
This will be a multi-center registry for patients with B-ALL. Patient data will be collected both retrospectively and prospectively.
- Trial name
- NCT07117136
- Where
- 5 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Medical College of Wisconsin
Acute Lymphoblastic Leukaemia
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
The ALL SCTped 2012 FORUM is a multinational, multi-centre, controlled, prospective phase III study for the therapy and therapy optimisation for children and adolescents with ALL in complete morphological remission (CR, less than…
- Trial name
- NCT01949129
- Testing
- VP16, TBI, Thiotepa
- Where
- 119 sites in Argentina, Australia and 29 more
- Volunteers
- 1,800 people
- Sponsor
- St. Anna Kinderkrebsforschung
Acute T Cell Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies
This study is a single-arm, open-label, non-randomized clinical trial aimed at evaluating the safety, tolerability and preliminary efficacy of HY035 cell injection in the treatment of patients with CD7-positive relapsed or…
- Conditions
- Acute T Cell Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory, Acute Myeloid Leukemia (AML), T Cell Lymphoma
- Trial name
- NCT07784309
- Testing
- HY035 cell injection
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Leukaemia (Acute Myeloid), Leukaemia (Acute Lymphoblastic)
Study of NK Cells in the Monitoring of Patients With Acute Leukemia or Myelodysplasia
The aim of the ENKLA-M study is to collect samples from patients with acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), and myelodysplastic syndrome (MDS) to study the evolution of blast phenotype (NK receptor…
- Conditions
- Leukaemia (Acute Myeloid), Leukaemia (Acute Lymphoblastic), Myelodysplastic Syndrome
- Trial name
- ENKLA-M (NCT07249476)
- Testing
- Bone marrow sampling (during routine care), Blood samples (during routine care)
- Where
- France
- Volunteers
- 55 people
- Sponsor
- Nantes University Hospital
Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukaemia
CAR-T Treatment in Pediatric and Adult Acute Lymphoblastic Leukemia
The goal of this observational study is to evaluate the efficacy of the treatment with approved CAR-T cells in Italy in pediatric and adult patients with acute B-cell lymphoblastic leukemia.
- Trial name
- NCT07623655
- Volunteers
- 107 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Lymphoblastic Leukaemia - Category
UNDERSTANDING THE T-CELL AND B-CELL RECEPTOR REPERTOIRE IN CHILDREN AND YOUNG ADULTS WITH ANTI-DRUG ANTIBODIES AGAINST PEG ASPARAGINASE
The aim of this sub study is to identify biomarkers in children and young adults with Acute Lymphoblastic Leukemia with hypersensitivity to PEG-asparaginase.
- Trial name
- NCT07499336
- Testing
- Hypersensitivity reaction to asparaginase
- Volunteers
- 45 people
- Sponsor
- Aarhus University Hospital
Leukaemia (Acute Lymphoblastic), Leukaemia (Acute Myeloid)
Phase I Clinical Trial of ThINKK Adoptive Immunotherapy After Allogeneic Hematopoietic Transplantation in Children With Leukemia or Neuroblastoma
A first-in-class adoptive immunotherapy we called ThINKK, for Therapeutic Inducers of Natural Killer (NK) cell Killing, have been designed for use after hematopoietic stem cell transplantation (HSCT), where the proper stimulation…
- Conditions
- Leukaemia (Acute Lymphoblastic), Leukaemia (Acute Myeloid), Neuroblastoma, Neuroblastoma, Metastatic
- Trial name
- ThINKK-01 (NCT07518654)
- Testing
- Therapeutic Inducers of Natural Killer Killing (ThINKK)
- Where
- 2 sites in Canada
- Volunteers
- 12 people
- Sponsor
- Michel Duval
B-Cell Acute Lymphoblastic Leukaemia
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
The IntReALL BCP 2020 study aims to review recent developments and findings regarding chemoimmunotherapy with inotuzumab and immunotherapy with blinatumomab and to increase the use of promising new immunotherapeutic drugs as…
- Trial name
- NCT07476729
- Testing
- Inotuzumab ozogamicin (INO), Blinatumomab
- Where
- 20 sites in Austria, Belgium and 18 more
- Volunteers
- 750 people
- Sponsor
- Charite University, Berlin, Germany
Acute Myeloblastic Leukaemia, Leukemia, T-Cell
Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).
This Phase I/IIa clinical study is testing an experimental treatment called GYA01 (CART84) for people with acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia (T-ALL) whose disease has come back after treatment…
- Trial name
- NCT07471789
- Testing
- CART84
- Where
- 2 sites in Spain
- Volunteers
- 33 people
- Sponsor
- Gyala Therapeutics
B-Cell ALL, B-Cell Acute Lymphoblastic Leukaemia
A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
The goal of this observational study is to establish a clear vaccination protocol for pediatric patients (less than 21 years old) who have received treatment for B-cell Acute Lymphoblastic Leukemia/Lymphoma.
- Conditions
- B-Cell ALL, B-Cell Acute Lymphoblastic Leukaemia, B-Cell Lymphoblastic Leukemia, B-Cell Lymphoblastic Leukemia/Lymphoma
- Trial name
- BOOSTER (NCT07422337)
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Arkansas Children's Hospital Research Institute
Acute Lymphoblastic Leukemia, Childhood Acute Leukemia
The Effect of Mandala on Anxiety and Fear Levels in Children With Leukemia Before Intrathecal Chemotherapy Treatment
This study aims to examine the effect of mandala coloring activity, administered before intrathecal chemotherapy treatment in children with leukemia, on pre-procedure anxiety and fear in children.
- Conditions
- Acute Lymphoblastic Leukemia, Childhood Acute Leukemia, Acute Myeloblastic Leukaemia
- Trial name
- NCT07203742
- Testing
- mandala painting
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Ege University
Acute Lymphoblastic Leukaemias (ALL), Long Term Follow-Up
Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphatic Leukemia Patients Using Ultrasound Localization Microscopy
With increasing survival rates in pediatric oncology, reports of long-term side effects persisting decades after treatment are also rising.
- Trial name
- HEALED (NCT07313878)
- Testing
- Ultrasound Localization Microscopy (ULM), Blood sample, Urinanalysis
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Acute Lymphobkastic Leukemia, Acute Lymphoblastic Leukaemia Recurrent
Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients
Relapsed/refractory acute lymphoblastic leukemia remains a challenge in the context of limited access to immunotherapy in developing countries.
- Conditions
- Acute Lymphobkastic Leukemia, Acute Lymphoblastic Leukaemia Recurrent, Philadelphia Chromosome Negative ALL
- Trial name
- NCT07039877
- Testing
- Venetoclax low dose with itraconazole
- Where
- Mexico
- Volunteers
- 12 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia
Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
This is a Phase 1, open-label, dose-escalation study to evaluate the safety, PK, PD and immunogenicity of CC312 following intravenous doses of CC312 in patients with relapsed and refractory (r/r) CD19 expressing B-cell…
- Conditions
- Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT06037018
- Testing
- CC312
- Where
- China
- Volunteers
- 44 people
- Sponsor
- CytoCares Inc
Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies
HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL.
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
- Trial name
- HEM-iSMART D (NCT05658640)
- Testing
- Trametinib, Dexamethasone, Cyclophosphamide
- Where
- 36 sites in Austria, Belgium and 13 more
- Volunteers
- 26 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL.
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
- Trial name
- HEM-iSMART C (NCT05745714)
- Testing
- Ruxolitinib, Venetoclax, Dexamethasone
- Where
- 33 sites in Austria, Belgium and 12 more
- Volunteers
- 26 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL.
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
- Trial name
- HEM-iSMART B (NCT05751044)
- Testing
- Dasatinib, Venetoclax, Dexamethasone
- Where
- 33 sites in Austria, Belgium and 12 more
- Volunteers
- 26 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL.
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent
- Trial name
- HEM-iSMART E (NCT07175415)
- Testing
- Capivasertib, Venetoclax, Dexamethasone
- Volunteers
- 42 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
Relapsed B Acute Lymphoblastic Leukaemia, Refractory B Acute Lymphoblastic Leukaemia
Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL
This is Phase II / III, Prospective, single arm, Open Label Study to Evaluate Safety and Efficacy of Intravenous Autologous CD19 CAR-T Cells for Relapsed / Refractory B-Acute Lymphoblastic Leukaemia
- Trial name
- NCT03937544
- Testing
- CD19 CAR-T CELLS, Cyclophosphamide, Fludarabine
- Where
- Malaysia
- Volunteers
- 10 people
- Sponsor
- National University of Malaysia